clinical trial · NCT06685536
A Long-term Follow-up Study in Participants Who Received CS-101
CorrectSequence Therapeutics Co., Ltd·—·enrolling by invitation·n = 5
Beta-ThalassemiaSafety and efficacy assessments
brief summary
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876),No investigational drug product will be administered in the study.
started
Jan 18, 2025
primary completion
Jul 1, 2039
completion
Jul 1, 2039
last updated
Feb 10, 2026
detailed description
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-06 (NCT06024876). Subjects in the CS-101-06 study will be entered into long-term follow-up of this study up to 15 years post-infusion at the completion of the last (12-month) followup visit after treatment with CS-101 Injection.
official title
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol